Cases involving SSRIs were significantly more likely to result in either minor or no outcomes, compared with bupropion
* For the secondary outcome, there was a significantly higher response rate in the aripiprazole group (74.3%) compared with the bupropion
switch group (62.4%) and bupropion
augmentation group (65.6%).
Trazadone (50 mg/day) was reinitiated, and bupropion
(150 mg/day) was added to the existing treatment.
Groups I, II, III, IV, V, VI, VII, and VIII received treatment of saline (control group), vehicle (5 % DMSO + 0.25 % Tween 80 + saline), hesperidin (1 mg/kg), agomelatine (8 mg/kg), hesperidin (0.5 mg/kg) + agomelatine (4 mg/kg), bupropion
(10 mg/kg), hesperidin (0.5 mg/kg) + bupropion
(5 mg/kg), and agomelatine (4 mg/kg) + bupropion
(5 mg/kg), respectively.
The trial showed no clinically significant difference in risk of adverse events across the smoking cessation treatments varenicline, bupropion
, nicotine patch, or placebo study arms, although the risk was higher in the psychiatric cohorts in each.
Anthenelli and his colleagues conducted a randomized, double-blind, triple-dummy, placebo- and active-controlled trial to assess bupropion
and varenicline in motivated smokers with and without psychiatric diagnoses for 12 weeks.
Findings from studies of bupropion
SR use showed mixed evidence for cardiovascular adverse events, with some trials finding a decreased risk for cardiovascular adverse events and others showing increased risk for such events (with borderline clinical significance).
"Our findings suggest that smokers trying to quit will have a better experience with varenicline as opposed to trying to quit on their own or by taking bupropion
. The more we can reduce these negative symptoms associated with quitting, the better the experience of the smoker and this may mean that even if they don't quit this time, they will be encouraged to try again."
is the only Food and Drug Administration (FDA)-approved antidepressant recommended as a first-line pharmacologic agent to assist with smoking cessation, based in part on a meta-analysis of 44 placebo-controlled RCTs (13,728 patients), which found that bupropion
had a relative risk (RR) of 1.62 for smoking cessation compared with placebo (95% confidence interval [CI], 1.491.76).
The study authors looked at the efficacy of combining the medications varenicline and bupropion
SR (sustained-release) for smoking cessation, compared with varenicline alone (monotherapy).
Separately, Wockhardt has received final approval from the FDA for marketing 100 mg, 150 mg and 200 mg 12-hour extended-release tablets of Bupropion
HCI, which is used in the treatment of depression.
In the recent decade, researchers have expressed renewed interest in therapeutic effects of bupropion
an atypical antidepressant and smoking cessation aid on these symptoms.